http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 21 Jul 2026 07:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Compugen+to+Participate+in+BTIG+Biotechnology+Conference+2026/26791971.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..holon" idsrc="xmltag.org" >HOLON, Israel</location></span>, <span class="legendSpanClass"><chron>July 21, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="http://www.cgen.com/" target="_blank" rel="nofollow"><span value="TelAviv:CGEN" idsrc="xmltag.org" >Compugen Ltd.</span></a> (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI/ML, today announced that management will present and hold 1x1 meetings at the <b><span>BTIG Biotechnology Conference</span> 2026</b> taking place virtually from <chron>July 28-29, 2026</chron>.</p> <p>Please reach out to your BTIG representative to request a meeting.</p><p>A replay for this event will not be available.</p><p><b>About Compugen</b></p><p>Compugen is a clinical-stage therapeutic discovery and development company utilizing Unigen™, its AI/ML powered computational discovery platform, to identify novel drug http://www.streetinsider.com/Press+Releases/Compugen+to+Participate+in+BTIG+Biotechnology+Conference+2026/26791971.html Tue, 21 Jul 2026 07:00:00 -0400 CGEN CGEN CW9 CW9 O.00653212 http://www.streetinsider.com/Press+Releases/Compugen+to+Participate+in+BTIG+Biotechnology+Conference+2026/26791971.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..holon" idsrc="xmltag.org" >HOLON, Israel</location></span>, <span class="legendSpanClass"><chron>July 21, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="http://www.cgen.com/" target="_blank" rel="nofollow"><span value="TelAviv:CGEN" idsrc="xmltag.org" >Compugen Ltd.</span></a> (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI/ML, today announced that management will present and hold 1x1 meetings at the <b><span>BTIG Biotechnology Conference</span> 2026</b> taking place virtually from <chron>July 28-29, 2026</chron>.</p> <p>Please reach out to your BTIG representative to request a meeting.</p><p>A replay for this event will not be available.</p><p><b>About Compugen</b></p><p>Compugen is a clinical-stage therapeutic discovery and development company utilizing Unigen™, its AI/ML powered computational discovery platform, to identify novel drug http://www.streetinsider.com/Press+Releases/Compugen+to+Participate+in+BTIG+Biotechnology+Conference+2026/26791971.html Tue, 21 Jul 2026 07:00:00 -0400 CGEN CGEN CW9 CW9 O.00653212 http://www.streetinsider.com/Press+Releases/Compugen+to+Participate+in+BTIG+Biotechnology+Conference+2026/26791971.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..holon" idsrc="xmltag.org" >HOLON, Israel</location></span>, <span class="legendSpanClass"><chron>July 21, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="http://www.cgen.com/" target="_blank" rel="nofollow"><span value="TelAviv:CGEN" idsrc="xmltag.org" >Compugen Ltd.</span></a> (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI/ML, today announced that management will present and hold 1x1 meetings at the <b><span>BTIG Biotechnology Conference</span> 2026</b> taking place virtually from <chron>July 28-29, 2026</chron>.</p> <p>Please reach out to your BTIG representative to request a meeting.</p><p>A replay for this event will not be available.</p><p><b>About Compugen</b></p><p>Compugen is a clinical-stage therapeutic discovery and development company utilizing Unigen™, its AI/ML powered computational discovery platform, to identify novel drug http://www.streetinsider.com/Press+Releases/Compugen+to+Participate+in+BTIG+Biotechnology+Conference+2026/26791971.html Tue, 21 Jul 2026 07:00:00 -0400 CGEN CGEN CW9 CW9 O.00653212 http://www.streetinsider.com/Press+Releases/Compugen+to+Participate+in+BTIG+Biotechnology+Conference+2026/26791971.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..holon" idsrc="xmltag.org" >HOLON, Israel</location></span>, <span class="legendSpanClass"><chron>July 21, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="http://www.cgen.com/" target="_blank" rel="nofollow"><span value="TelAviv:CGEN" idsrc="xmltag.org" >Compugen Ltd.</span></a> (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI/ML, today announced that management will present and hold 1x1 meetings at the <b><span>BTIG Biotechnology Conference</span> 2026</b> taking place virtually from <chron>July 28-29, 2026</chron>.</p> <p>Please reach out to your BTIG representative to request a meeting.</p><p>A replay for this event will not be available.</p><p><b>About Compugen</b></p><p>Compugen is a clinical-stage therapeutic discovery and development company utilizing Unigen™, its AI/ML powered computational discovery platform, to identify novel drug http://www.streetinsider.com/Press+Releases/Compugen+to+Participate+in+BTIG+Biotechnology+Conference+2026/26791971.html Tue, 21 Jul 2026 07:00:00 -0400 CGEN CGEN CW9 CW9 O.00653212 http://www.streetinsider.com/Press+Releases/Compugen+to+Participate+in+BTIG+Biotechnology+Conference+2026/26791971.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..holon" idsrc="xmltag.org" >HOLON, Israel</location></span>, <span class="legendSpanClass"><chron>July 21, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="http://www.cgen.com/" target="_blank" rel="nofollow"><span value="TelAviv:CGEN" idsrc="xmltag.org" >Compugen Ltd.</span></a> (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI/ML, today announced that management will present and hold 1x1 meetings at the <b><span>BTIG Biotechnology Conference</span> 2026</b> taking place virtually from <chron>July 28-29, 2026</chron>.</p> <p>Please reach out to your BTIG representative to request a meeting.</p><p>A replay for this event will not be available.</p><p><b>About Compugen</b></p><p>Compugen is a clinical-stage therapeutic discovery and development company utilizing Unigen™, its AI/ML powered computational discovery platform, to identify novel drug http://www.streetinsider.com/Press+Releases/Compugen+to+Participate+in+BTIG+Biotechnology+Conference+2026/26791971.html Tue, 21 Jul 2026 07:00:00 -0400 CGEN CGEN CW9 CW9 O.00653212 http://www.streetinsider.com/PRNewswire/Compugen+to+Participate+in+BTIG+Biotechnology+Conference+2026/26791971.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..holon" idsrc="xmltag.org" >HOLON, Israel</location></span>, <span class="legendSpanClass"><chron>July 21, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="http://www.cgen.com/" target="_blank" rel="nofollow"><span value="TelAviv:CGEN" idsrc="xmltag.org" >Compugen Ltd.</span></a> (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI/ML, today announced that management will present and hold 1x1 meetings at the <b><span>BTIG Biotechnology Conference</span> 2026</b> taking place virtually from <chron>July 28-29, 2026</chron>.</p> <p>Please reach out to your BTIG representative to request a meeting.</p><p>A replay for this event will not be available.</p><p><b>About Compugen</b></p><p>Compugen is a clinical-stage therapeutic discovery and development company utilizing Unigen™, its AI/ML powered computational discovery platform, to identify novel drug http://www.streetinsider.com/PRNewswire/Compugen+to+Participate+in+BTIG+Biotechnology+Conference+2026/26791971.html Tue, 21 Jul 2026 07:00:00 -0400 CGEN CGEN CW9 CW9 O.00653212 http://www.streetinsider.com/PRNewswire/Compugen+to+Participate+in+BTIG+Biotechnology+Conference+2026/26791971.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..holon" idsrc="xmltag.org" >HOLON, Israel</location></span>, <span class="legendSpanClass"><chron>July 21, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="http://www.cgen.com/" target="_blank" rel="nofollow"><span value="TelAviv:CGEN" idsrc="xmltag.org" >Compugen Ltd.</span></a> (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI/ML, today announced that management will present and hold 1x1 meetings at the <b><span>BTIG Biotechnology Conference</span> 2026</b> taking place virtually from <chron>July 28-29, 2026</chron>.</p> <p>Please reach out to your BTIG representative to request a meeting.</p><p>A replay for this event will not be available.</p><p><b>About Compugen</b></p><p>Compugen is a clinical-stage therapeutic discovery and development company utilizing Unigen™, its AI/ML powered computational discovery platform, to identify novel drug http://www.streetinsider.com/PRNewswire/Compugen+to+Participate+in+BTIG+Biotechnology+Conference+2026/26791971.html Tue, 21 Jul 2026 07:00:00 -0400 CGEN CGEN CW9 CW9 O.00653212 http://www.streetinsider.com/PRNewswire/Compugen+to+Participate+in+BTIG+Biotechnology+Conference+2026/26791971.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..holon" idsrc="xmltag.org" >HOLON, Israel</location></span>, <span class="legendSpanClass"><chron>July 21, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="http://www.cgen.com/" target="_blank" rel="nofollow"><span value="TelAviv:CGEN" idsrc="xmltag.org" >Compugen Ltd.</span></a> (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI/ML, today announced that management will present and hold 1x1 meetings at the <b><span>BTIG Biotechnology Conference</span> 2026</b> taking place virtually from <chron>July 28-29, 2026</chron>.</p> <p>Please reach out to your BTIG representative to request a meeting.</p><p>A replay for this event will not be available.</p><p><b>About Compugen</b></p><p>Compugen is a clinical-stage therapeutic discovery and development company utilizing Unigen™, its AI/ML powered computational discovery platform, to identify novel drug http://www.streetinsider.com/PRNewswire/Compugen+to+Participate+in+BTIG+Biotechnology+Conference+2026/26791971.html Tue, 21 Jul 2026 07:00:00 -0400 CGEN CGEN CW9 CW9 O.00653212 http://www.streetinsider.com/PRNewswire/Compugen+to+Participate+in+BTIG+Biotechnology+Conference+2026/26791971.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..holon" idsrc="xmltag.org" >HOLON, Israel</location></span>, <span class="legendSpanClass"><chron>July 21, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="http://www.cgen.com/" target="_blank" rel="nofollow"><span value="TelAviv:CGEN" idsrc="xmltag.org" >Compugen Ltd.</span></a> (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI/ML, today announced that management will present and hold 1x1 meetings at the <b><span>BTIG Biotechnology Conference</span> 2026</b> taking place virtually from <chron>July 28-29, 2026</chron>.</p> <p>Please reach out to your BTIG representative to request a meeting.</p><p>A replay for this event will not be available.</p><p><b>About Compugen</b></p><p>Compugen is a clinical-stage therapeutic discovery and development company utilizing Unigen™, its AI/ML powered computational discovery platform, to identify novel drug http://www.streetinsider.com/PRNewswire/Compugen+to+Participate+in+BTIG+Biotechnology+Conference+2026/26791971.html Tue, 21 Jul 2026 07:00:00 -0400 CGEN CGEN CW9 CW9 O.00653212 http://www.streetinsider.com/PRNewswire/Compugen+to+Participate+in+BTIG+Biotechnology+Conference+2026/26791971.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..holon" idsrc="xmltag.org" >HOLON, Israel</location></span>, <span class="legendSpanClass"><chron>July 21, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="http://www.cgen.com/" target="_blank" rel="nofollow"><span value="TelAviv:CGEN" idsrc="xmltag.org" >Compugen Ltd.</span></a> (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI/ML, today announced that management will present and hold 1x1 meetings at the <b><span>BTIG Biotechnology Conference</span> 2026</b> taking place virtually from <chron>July 28-29, 2026</chron>.</p> <p>Please reach out to your BTIG representative to request a meeting.</p><p>A replay for this event will not be available.</p><p><b>About Compugen</b></p><p>Compugen is a clinical-stage therapeutic discovery and development company utilizing Unigen™, its AI/ML powered computational discovery platform, to identify novel drug http://www.streetinsider.com/PRNewswire/Compugen+to+Participate+in+BTIG+Biotechnology+Conference+2026/26791971.html Tue, 21 Jul 2026 07:00:00 -0400 CGEN CGEN CW9 CW9 O.00653212 http://www.streetinsider.com/Press+Releases/Compugen+to+Release+Second+Quarter+2026+Results+on+Monday%2C+August+3%2C+2026/26786813.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..holon" idsrc="xmltag.org" >HOLON, Israel</location></span>, <span class="legendSpanClass"><chron>July 20, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="http://www.cgen.com/" target="_blank" rel="nofollow"><span value="TelAviv:CGEN" idsrc="xmltag.org" >Compugen Ltd.</span></a> (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/ML, today announced that the Company will release its second quarter 2026 financial results on <chron>Monday, August 3, 2026</chron>, before the <location value="LC/us" idsrc="xmltag.org" >U.S</location>. financial markets open. Management will host a conference call and webcast to review the results and provide a corporate update at <chron>8:30 AM ET</chron>.</p> <p>To access the live conference call by telephone, please dial 1-866-744-5399 from http://www.streetinsider.com/Press+Releases/Compugen+to+Release+Second+Quarter+2026+Results+on+Monday%2C+August+3%2C+2026/26786813.html Mon, 20 Jul 2026 07:00:00 -0400 CGEN CGEN O.00653212 http://www.streetinsider.com/Press+Releases/Compugen+to+Release+Second+Quarter+2026+Results+on+Monday%2C+August+3%2C+2026/26786813.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..holon" idsrc="xmltag.org" >HOLON, Israel</location></span>, <span class="legendSpanClass"><chron>July 20, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="http://www.cgen.com/" target="_blank" rel="nofollow"><span value="TelAviv:CGEN" idsrc="xmltag.org" >Compugen Ltd.</span></a> (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/ML, today announced that the Company will release its second quarter 2026 financial results on <chron>Monday, August 3, 2026</chron>, before the <location value="LC/us" idsrc="xmltag.org" >U.S</location>. financial markets open. Management will host a conference call and webcast to review the results and provide a corporate update at <chron>8:30 AM ET</chron>.</p> <p>To access the live conference call by telephone, please dial 1-866-744-5399 from http://www.streetinsider.com/Press+Releases/Compugen+to+Release+Second+Quarter+2026+Results+on+Monday%2C+August+3%2C+2026/26786813.html Mon, 20 Jul 2026 07:00:00 -0400 CGEN CGEN O.00653212 http://www.streetinsider.com/Press+Releases/Compugen+to+Release+Second+Quarter+2026+Results+on+Monday%2C+August+3%2C+2026/26786813.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..holon" idsrc="xmltag.org" >HOLON, Israel</location></span>, <span class="legendSpanClass"><chron>July 20, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="http://www.cgen.com/" target="_blank" rel="nofollow"><span value="TelAviv:CGEN" idsrc="xmltag.org" >Compugen Ltd.</span></a> (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/ML, today announced that the Company will release its second quarter 2026 financial results on <chron>Monday, August 3, 2026</chron>, before the <location value="LC/us" idsrc="xmltag.org" >U.S</location>. financial markets open. Management will host a conference call and webcast to review the results and provide a corporate update at <chron>8:30 AM ET</chron>.</p> <p>To access the live conference call by telephone, please dial 1-866-744-5399 from http://www.streetinsider.com/Press+Releases/Compugen+to+Release+Second+Quarter+2026+Results+on+Monday%2C+August+3%2C+2026/26786813.html Mon, 20 Jul 2026 07:00:00 -0400 CGEN CGEN O.00653212 http://www.streetinsider.com/PRNewswire/Compugen+to+Release+Second+Quarter+2026+Results+on+Monday%2C+August+3%2C+2026/26786813.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..holon" idsrc="xmltag.org" >HOLON, Israel</location></span>, <span class="legendSpanClass"><chron>July 20, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="http://www.cgen.com/" target="_blank" rel="nofollow"><span value="TelAviv:CGEN" idsrc="xmltag.org" >Compugen Ltd.</span></a> (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/ML, today announced that the Company will release its second quarter 2026 financial results on <chron>Monday, August 3, 2026</chron>, before the <location value="LC/us" idsrc="xmltag.org" >U.S</location>. financial markets open. Management will host a conference call and webcast to review the results and provide a corporate update at <chron>8:30 AM ET</chron>.</p> <p>To access the live conference call by telephone, please dial 1-866-744-5399 from http://www.streetinsider.com/PRNewswire/Compugen+to+Release+Second+Quarter+2026+Results+on+Monday%2C+August+3%2C+2026/26786813.html Mon, 20 Jul 2026 07:00:00 -0400 CGEN CGEN O.00653212 http://www.streetinsider.com/PRNewswire/Compugen+to+Release+Second+Quarter+2026+Results+on+Monday%2C+August+3%2C+2026/26786813.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..holon" idsrc="xmltag.org" >HOLON, Israel</location></span>, <span class="legendSpanClass"><chron>July 20, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="http://www.cgen.com/" target="_blank" rel="nofollow"><span value="TelAviv:CGEN" idsrc="xmltag.org" >Compugen Ltd.</span></a> (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/ML, today announced that the Company will release its second quarter 2026 financial results on <chron>Monday, August 3, 2026</chron>, before the <location value="LC/us" idsrc="xmltag.org" >U.S</location>. financial markets open. Management will host a conference call and webcast to review the results and provide a corporate update at <chron>8:30 AM ET</chron>.</p> <p>To access the live conference call by telephone, please dial 1-866-744-5399 from http://www.streetinsider.com/PRNewswire/Compugen+to+Release+Second+Quarter+2026+Results+on+Monday%2C+August+3%2C+2026/26786813.html Mon, 20 Jul 2026 07:00:00 -0400 CGEN CGEN O.00653212 http://www.streetinsider.com/PRNewswire/Compugen+to+Release+Second+Quarter+2026+Results+on+Monday%2C+August+3%2C+2026/26786813.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..holon" idsrc="xmltag.org" >HOLON, Israel</location></span>, <span class="legendSpanClass"><chron>July 20, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="http://www.cgen.com/" target="_blank" rel="nofollow"><span value="TelAviv:CGEN" idsrc="xmltag.org" >Compugen Ltd.</span></a> (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/ML, today announced that the Company will release its second quarter 2026 financial results on <chron>Monday, August 3, 2026</chron>, before the <location value="LC/us" idsrc="xmltag.org" >U.S</location>. financial markets open. Management will host a conference call and webcast to review the results and provide a corporate update at <chron>8:30 AM ET</chron>.</p> <p>To access the live conference call by telephone, please dial 1-866-744-5399 from http://www.streetinsider.com/PRNewswire/Compugen+to+Release+Second+Quarter+2026+Results+on+Monday%2C+August+3%2C+2026/26786813.html Mon, 20 Jul 2026 07:00:00 -0400 CGEN CGEN O.00653212 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++COMPUGEN+LTD++++++++++++++For%3A+Jul+09++Filed+by%3A+Levine+Zurit/26762410.html si-local-file:///var/storage/secattach/20260713/26762410.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++COMPUGEN+LTD++++++++++++++For%3A+Jul+09++Filed+by%3A+Levine+Zurit/26762410.html Mon, 13 Jul 2026 16:02:00 -0400 CGEN CGEN O.00653212 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++COMPUGEN+LTD++++++++++++++For%3A+Jul+09++Filed+by%3A+Levine+Zurit/26762410.html si-local-file:///var/storage/secattach/20260713/26762410.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++COMPUGEN+LTD++++++++++++++For%3A+Jul+09++Filed+by%3A+Levine+Zurit/26762410.html Mon, 13 Jul 2026 16:02:00 -0400 CGEN CGEN O.00653212 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++COMPUGEN+LTD++++++++++++++For%3A+Jul+09++Filed+by%3A+Levine+Zurit/26762410.html si-local-file:///var/storage/secattach/20260713/26762410.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++COMPUGEN+LTD++++++++++++++For%3A+Jul+09++Filed+by%3A+Levine+Zurit/26762410.html Mon, 13 Jul 2026 16:02:00 -0400 CGEN CGEN O.00653212 http://www.streetinsider.com/Corporate+News/Compugen+presents+COM701+ovarian+cancer+trial+poster+at+ESMO/26662668.html <p>Compugen Ltd. (Nasdaq: CGEN) presented a trial-in-progress poster on the MAIA-ovarian adaptive platform trial at the ESMO Gynaecological Cancers Congress 2026 in Copenhagen, Denmark, on June 18.</p><p>The poster, presented by Dr. Oladapo Yeku of Massachusetts General Hospital in Boston, covered the randomized trial evaluating COM701 as a maintenance therapy in patients with relapsed platinum-sensitive ovarian cancer. The trial is registered under NCT06888921.</p><p>COM701 is an anti-PVRIG antibody that Compugen describes as a potential first-in-class therapy. It has been evaluated in Phase 1 clinical studies as monotherapy and in combination, with results showing signs of anti-tumor activity and a tolerability profile that http://www.streetinsider.com/Corporate+News/Compugen+presents+COM701+ovarian+cancer+trial+poster+at+ESMO/26662668.html Thu, 18 Jun 2026 07:00:57 -0400 CGEN http://www.streetinsider.com/FDA/Compugen+presents+COM701+ovarian+cancer+trial+poster+at+ESMO/26662668.html <p>Compugen Ltd. (Nasdaq: CGEN) presented a trial-in-progress poster on the MAIA-ovarian adaptive platform trial at the ESMO Gynaecological Cancers Congress 2026 in Copenhagen, Denmark, on June 18.</p><p>The poster, presented by Dr. Oladapo Yeku of Massachusetts General Hospital in Boston, covered the randomized trial evaluating COM701 as a maintenance therapy in patients with relapsed platinum-sensitive ovarian cancer. The trial is registered under NCT06888921.</p><p>COM701 is an anti-PVRIG antibody that Compugen describes as a potential first-in-class therapy. It has been evaluated in Phase 1 clinical studies as monotherapy and in combination, with results showing signs of anti-tumor activity and a tolerability profile that http://www.streetinsider.com/FDA/Compugen+presents+COM701+ovarian+cancer+trial+poster+at+ESMO/26662668.html Thu, 18 Jun 2026 07:00:57 -0400 CGEN http://www.streetinsider.com/Press+Releases/Compugen+Presents+a+Trial-in-Progress+Poster+on+the+MAIA-ovarian+Adaptive+Platform+Trial+at+ESMO+Gynaecological+Cancers+Congress/26662623.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..holon" idsrc="xmltag.org" >HOLON, Israel</location></span>, <span class="legendSpanClass"><chron>June 18, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://cgen.com/overview/default.aspx" target="_blank" rel="nofollow"><span value="TelAviv:CGEN" idsrc="xmltag.org" >Compugen Ltd.</span></a> (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/ML, today presented a trial-in-progress poster on the MAIA-ovarian adaptive platform trial of COM701, a potential first-in-class anti-PVRIG antibody, at the <span>ESMO Gynaecological Cancers Congress</span> 2026, in <location value="LU/dk..cophgn" idsrc="xmltag.org" >Copenhagen, Denmark</location>.</p> <p>"We believe there is a strong biologic and clinical rationale for the MAIA-ovarian trial in relapsed platinum-sensitive ovarian cancer, where no standard of care for this maintenance setting http://www.streetinsider.com/Press+Releases/Compugen+Presents+a+Trial-in-Progress+Poster+on+the+MAIA-ovarian+Adaptive+Platform+Trial+at+ESMO+Gynaecological+Cancers+Congress/26662623.html Thu, 18 Jun 2026 07:00:00 -0400 A.40221050 CGEN CGEN CW9 CW9 O.00653212 O.20042365 http://www.streetinsider.com/Press+Releases/Compugen+Presents+a+Trial-in-Progress+Poster+on+the+MAIA-ovarian+Adaptive+Platform+Trial+at+ESMO+Gynaecological+Cancers+Congress/26662623.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..holon" idsrc="xmltag.org" >HOLON, Israel</location></span>, <span class="legendSpanClass"><chron>June 18, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://cgen.com/overview/default.aspx" target="_blank" rel="nofollow"><span value="TelAviv:CGEN" idsrc="xmltag.org" >Compugen Ltd.</span></a> (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/ML, today presented a trial-in-progress poster on the MAIA-ovarian adaptive platform trial of COM701, a potential first-in-class anti-PVRIG antibody, at the <span>ESMO Gynaecological Cancers Congress</span> 2026, in <location value="LU/dk..cophgn" idsrc="xmltag.org" >Copenhagen, Denmark</location>.</p> <p>"We believe there is a strong biologic and clinical rationale for the MAIA-ovarian trial in relapsed platinum-sensitive ovarian cancer, where no standard of care for this maintenance setting http://www.streetinsider.com/Press+Releases/Compugen+Presents+a+Trial-in-Progress+Poster+on+the+MAIA-ovarian+Adaptive+Platform+Trial+at+ESMO+Gynaecological+Cancers+Congress/26662623.html Thu, 18 Jun 2026 07:00:00 -0400 A.40221050 CGEN CGEN CW9 CW9 O.00653212 O.20042365 http://www.streetinsider.com/Press+Releases/Compugen+Presents+a+Trial-in-Progress+Poster+on+the+MAIA-ovarian+Adaptive+Platform+Trial+at+ESMO+Gynaecological+Cancers+Congress/26662623.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..holon" idsrc="xmltag.org" >HOLON, Israel</location></span>, <span class="legendSpanClass"><chron>June 18, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://cgen.com/overview/default.aspx" target="_blank" rel="nofollow"><span value="TelAviv:CGEN" idsrc="xmltag.org" >Compugen Ltd.</span></a> (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/ML, today presented a trial-in-progress poster on the MAIA-ovarian adaptive platform trial of COM701, a potential first-in-class anti-PVRIG antibody, at the <span>ESMO Gynaecological Cancers Congress</span> 2026, in <location value="LU/dk..cophgn" idsrc="xmltag.org" >Copenhagen, Denmark</location>.</p> <p>"We believe there is a strong biologic and clinical rationale for the MAIA-ovarian trial in relapsed platinum-sensitive ovarian cancer, where no standard of care for this maintenance setting http://www.streetinsider.com/Press+Releases/Compugen+Presents+a+Trial-in-Progress+Poster+on+the+MAIA-ovarian+Adaptive+Platform+Trial+at+ESMO+Gynaecological+Cancers+Congress/26662623.html Thu, 18 Jun 2026 07:00:00 -0400 A.40221050 CGEN CGEN CW9 CW9 O.00653212 O.20042365 http://www.streetinsider.com/Press+Releases/Compugen+Presents+a+Trial-in-Progress+Poster+on+the+MAIA-ovarian+Adaptive+Platform+Trial+at+ESMO+Gynaecological+Cancers+Congress/26662623.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..holon" idsrc="xmltag.org" >HOLON, Israel</location></span>, <span class="legendSpanClass"><chron>June 18, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://cgen.com/overview/default.aspx" target="_blank" rel="nofollow"><span value="TelAviv:CGEN" idsrc="xmltag.org" >Compugen Ltd.</span></a> (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/ML, today presented a trial-in-progress poster on the MAIA-ovarian adaptive platform trial of COM701, a potential first-in-class anti-PVRIG antibody, at the <span>ESMO Gynaecological Cancers Congress</span> 2026, in <location value="LU/dk..cophgn" idsrc="xmltag.org" >Copenhagen, Denmark</location>.</p> <p>"We believe there is a strong biologic and clinical rationale for the MAIA-ovarian trial in relapsed platinum-sensitive ovarian cancer, where no standard of care for this maintenance setting http://www.streetinsider.com/Press+Releases/Compugen+Presents+a+Trial-in-Progress+Poster+on+the+MAIA-ovarian+Adaptive+Platform+Trial+at+ESMO+Gynaecological+Cancers+Congress/26662623.html Thu, 18 Jun 2026 07:00:00 -0400 A.40221050 CGEN CGEN CW9 CW9 O.00653212 O.20042365